ACTUATE THERAPEUTICS, INC.

ACTU · Nasdaq · SIC 2834: Pharmaceutical Preparations
36
SEC Filings

Business Summary

PART I . Overview Class-Leading GSK-3 Inhibitor We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (GSK-3), a master regulator of complex biological signaling cascades, inclu...

Next Earnings

Q2 FY2026 — expected 2026-09-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionACTUdiscussed_in_filing Artificial Intelligence
topic_mentionACTUdiscussed_in_filing Cybersecurity
topic_mentionACTUdiscussed_in_filing Trusted Computing
topic_mentionACTUdiscussed_in_filing Blockchain & Crypto
topic_mentionACTUdiscussed_in_filing Regulation
topic_mentionACTUdiscussed_in_filing Healthcare & Bio
topic_mentionACTUdiscussed_in_filing Platform & Ecosystem
topic_mentionACTUdiscussed_in_filing Sovereign & Government
topic_mentionACTUdiscussed_in_filing Artificial Intelligence
topic_mentionACTUdiscussed_in_filing Cybersecurity
topic_mentionACTUdiscussed_in_filing Trusted Computing
topic_mentionACTUdiscussed_in_filing Blockchain & Crypto
topic_mentionACTUdiscussed_in_filing Regulation
topic_mentionACTUdiscussed_in_filing Healthcare & Bio
topic_mentionACTUdiscussed_in_filing Platform & Ecosystem
topic_mentionACTUdiscussed_in_filing Sovereign & Government
topic_mentionACTUdiscussed_in_filing Artificial Intelligence
topic_mentionACTUdiscussed_in_filing Cybersecurity
topic_mentionACTUdiscussed_in_filing Trusted Computing
topic_mentionACTUdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-262025-12-310001683168-26-002257EDGAR79K words
2025-03-132024-12-310001683168-25-001581EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001683168-25-008323EDGAR24K words
2025-08-142025-06-300001683168-25-006159EDGAR—
2025-05-152025-03-310001683168-25-003705EDGAR—
2024-11-132024-09-300001683168-24-007971EDGAR—
2024-09-242024-06-300001683168-24-006623EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-01-120001683168-26-000217EDGAR1K words
2025-11-280001683168-25-008732EDGAR—
2025-11-210001683168-25-008618EDGAR—
2025-09-100001683168-25-006831EDGAR—
2025-06-260001683168-25-004766EDGAR—
2025-06-050001683168-25-004258EDGAR—
2025-06-020001683168-25-004117EDGAR—
2025-05-230001683168-25-003995EDGAR—
2025-05-060001683168-25-003163EDGAR—
2025-03-280001683168-25-001945EDGAR—

36 total filings indexed. 19 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC. AEON — AEON Biopharma, Inc.

Company Identity

CIK0001652935
TickerACTU
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f13473a75bad387a1d7263e88ecede1ec5d8f0d0d8f0abc4f8423d980d76fbcd
parent: c4897c8f309b58663f9b0f08b219772308bf697fb74f852c9d1f02d4f8919fb1
content hash: d6410870761e364effc66791e2659603a9b0aee192bf5f1ca9dfc2c81f7fc6e5
signed: 2026-04-13T04:43:27.355Z
sources: 7 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf